- Home
- JLL vs HOLX Comparison
JLL vs HOLX Comparison
Compare JLL & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- HOLX
- Stock Information
- Founded
- JLL 1997
- HOLX 1985
- Country
- JLL United States
- HOLX United States
- Employees
- JLL N/A
- HOLX N/A
- Industry
- JLL Real Estate
- HOLX Medical Electronics
- Sector
- JLL Finance
- HOLX Health Care
- Exchange
- JLL Nasdaq
- HOLX Nasdaq
- Market Cap
- JLL 12.1B
- HOLX 14.5B
- IPO Year
- JLL 1997
- HOLX 1990
- Fundamental
- Price
- JLL $255.83
- HOLX $64.62
- Analyst Decision
- JLL Strong Buy
- HOLX Buy
- Analyst Count
- JLL 7
- HOLX 13
- Target Price
- JLL $310.00
- HOLX $77.73
- AVG Volume (30 Days)
- JLL 490.0K
- HOLX 2.4M
- Earning Date
- JLL 08-06-2025
- HOLX 07-30-2025
- Dividend Yield
- JLL N/A
- HOLX N/A
- EPS Growth
- JLL 78.40
- HOLX 25.36
- EPS
- JLL 11.07
- HOLX 2.39
- Revenue
- JLL $24,054,800,000.00
- HOLX $4,026,500,000.00
- Revenue This Year
- JLL $10.02
- HOLX $2.99
- Revenue Next Year
- JLL $8.25
- HOLX $4.91
- P/E Ratio
- JLL $23.22
- HOLX $27.23
- Revenue Growth
- JLL 13.63
- HOLX 1.66
- 52 Week Low
- JLL $194.36
- HOLX $51.90
- 52 Week High
- JLL $288.50
- HOLX $84.67
- Technical
- Relative Strength Index (RSI)
- JLL 59.72
- HOLX 52.45
- Support Level
- JLL $251.91
- HOLX $64.05
- Resistance Level
- JLL $261.32
- HOLX $67.06
- Average True Range (ATR)
- JLL 5.41
- HOLX 1.31
- MACD
- JLL -0.30
- HOLX -0.18
- Stochastic Oscillator
- JLL 66.09
- HOLX 27.81
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.